Clinical study of glecaprevir/pibrentasvir in the treatment of patients with hepatitis C virus and human immunodeficiency virus co-infection
10.12138/j.issn.1671-9638.20244568
- VernacularTitle:格卡瑞韦/哌仑他韦治疗HCV/HIV合并感染患者的临床研究
- Author:
Jun RUAN
1
;
Guo-Xian KOU
;
Heng YIN
;
Rui SU
;
Cheng-Bin YANG
Author Information
1. 电子科技大学医学院附属绵阳医院绵阳市中心医院感染科,四川绵阳 621000
- Keywords:
hepatitis C virus;
human immunodeficiency virus;
glecaprevir/pibrentasvir;
clinical research;
viro-logical response rate
- From:
Chinese Journal of Infection Control
2024;23(5):563-567
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical efficacy and safety of glecaprevir/pibrentasvir in the treatment of pa-tients with hepatitis C virus(HCV)and human immunodeficiency virus(HIV)co-infection,and provide scientific basis for clinical treatment.Methods 89 initially treated non-cirrhotic patients with HCV/HIV co-infection in a hospital of Butuo County of Liangshan Prefecture from January 2021 to January 2022 were selected.All patients re-ceived glecaprevir/pibrentasvir treatment for 8 weeks and were followed up for 12 weeks.Virological response rate at the end-of-treatment and sustained virological response rate after 12 weeks(SVR12)of treatment as well as oc-currence of adverse reaction were recorded.Results Among 89 initially treated non-cirrhotic patients with HCV/HIV co-infection,most were middle-aged and young married men(n=79,88.8％).HIV was mainly transmitted through sexual contact(n=62,69.7％)and intravenous drug use(n=27,30.3％).The most common HCV geno-types were genotype 1b(n=33,37.1％)and genotype 3b(n=25,28.1％).All patients completed 8 weeks of treatment successfully and HCV RNA load at the end of treatment was below the detection limit(＜25 IU/mL).Eight patients failed to complete the follow-up,and the remaining 81(100％)patients achieved a sustained virologic re-sponse.There were no serious adverse reactions during the observation period,but 11 patients had mild adverse re-actions.Conclusion The 8-week treatment regimen of glecaprevir/pibrentasvir for non-cirrhotic patients with geno-type 1,3,and 6 HCV/HIV co-infection can achieve 100％SVR12,with high safety and tolerability,which can be used as a good choice for clinical treatment of these patients.
